Production (Stage)
Elevation Oncology, Inc.
ELEV
$0.3817
$0.00150.40%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.47% | 8.06% | -2.03% | -8.27% | -12.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.42% | 10.82% | -17.52% | -49.46% | -56.58% |
| Operating Income | -18.42% | -10.82% | 17.52% | 49.46% | 56.58% |
| Income Before Tax | -21.96% | 2.70% | 26.22% | 53.35% | 58.54% |
| Income Tax Expenses | 5.56% | 43.33% | -6.52% | 20.00% | 20.00% |
| Earnings from Continuing Operations | -21.95% | 2.67% | 26.21% | 53.32% | 58.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.95% | 2.67% | 26.21% | 53.32% | 58.52% |
| EBIT | -18.42% | -10.82% | 17.52% | 49.46% | 56.58% |
| EBITDA | -18.49% | -10.87% | 17.51% | 49.47% | 56.60% |
| EPS Basic | 18.79% | 48.63% | 63.28% | 76.96% | 75.40% |
| Normalized Basic EPS | 23.09% | 41.49% | 60.10% | 76.02% | 74.50% |
| EPS Diluted | 18.79% | 48.63% | 63.28% | 76.96% | 75.40% |
| Normalized Diluted EPS | 23.09% | 41.49% | 60.10% | 76.02% | 74.50% |
| Average Basic Shares Outstanding | 43.26% | 67.39% | 80.38% | 98.39% | 76.57% |
| Average Diluted Shares Outstanding | 43.26% | 67.39% | 80.38% | 98.39% | 76.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |